ArticleMolecular cancer therapeutics2025

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.

Susana S Najera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.